SIRION Biotech Granted CIR accreditation by French Ministry of Higher Education, Research and Innovation
Munich, October 8, 2021: The French Ministry of Higher Education, Research and Innovation have granted SIRION Biotech a 3-year CIR (Crédit Impôt Recherche) accreditation lasting until end of 2023.
As a result, SIRION Biotech GmbH is now on a list of experts accessible on the Ministry website, and companies based in France that work with us can deduct part of the research funds spent at SIRION Biotech from their taxes. This accreditation is the result of SIRION’s drive to improve support for clients in France and Worldwide, enabling them to go one step closer to developing cutting edge therapies with efficient viral vector technologies.
“It is a great achievement for us in France, a country we believe to be one of the most important in the Gene Therapy and Cell Therapy markets. With this accreditation we reinforce our support to French companies and open new paths towards more R&D collaborations.”, said CEO of SIRION Biotech, Dr. Christian Thirion.
Dr. Francois Vromman, Senior Director, Head of Business Operations, Southern and Western Europe, and Head of SIRION Biotech’s Paris office, added: “We wish to thank the @Businove team with @Romain Bouverot and @Angelique Richard for helping us through the process”
About SIRION Biotech GmbH
SIRION Biotech was founded in 2005 to lead the next generation of viral vector technologies for gene and cell therapy as well as vaccine development. Now SIRION offers one of the world’s most comprehensive viral vector technology platforms based on lenti-, adeno-, and adeno-associated viruses to expedite gene therapy research and advance drug development. SIRION is becoming a partner of choice in this growing sector. LentiBOOST® has been used in a number of clinical trials from early stage clinical Phase 1/2 through late stage clinical Phase 3 trials and demonstrated clinical success in improving transduction of the therapeutic vector.